title: Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials.
abstract: BACKGROUND
  The Nobori is a new-generation, biodegradable-polymer coated, biolimus-eluting stent (BES) that has recently been investigated in several randomized trials with inconsistent results. The aim of this study was to assess the efficacy and safety of Nobori BES versus other drug-eluting stents (DES) in patients treated with percutaneous coronary intervention (PCI).
  
  
  METHODS
  We undertook a meta-analysis of randomized trials investigating Nobori BES versus other DES. Primary efficacy and safety outcomes were target lesion revascularization (TLR) and definite/probable stent thrombosis (ST), respectively. Secondary outcomes were the composite of cardiac death/myocardial infarction (MI)/target vessel revascularization (TVR), MI and death.
  
  
  RESULTS
  A total of 9114 PCI-patients randomly received Nobori BES (n=5080) or other DES (n=4034). This latter group comprised patients receiving everolimus- (n=2533), sirolimus- (n=1376) or paclitaxel-eluting stents (n=125). Median follow-up was 11 months [interquartile range 9-12]. The Nobori BES versus other DES showed comparable risk of TLR (odds ratio [95% confidence interval]=0.91 [0.57-1.46], p=0.71). There was significant heterogeneity across trials due to significant lower TLR risk with Nobori BES versus paclitaxel-eluting stent (0.32 [0.10-0.98], p=0.046; p for interaction=0.009). Nobori BES versus other DES showed comparable risk of definite/probable ST (1.40 [0.66-2.97], p=0.39), cardiac death/MI/TVR (1.05 [0.88-1.25], p=0.59), MI (1.13 [0.87-1.48], p=0.37) and death (1.09 [0.81-1.48], p=0.56).
  
  
  CONCLUSIONS
  Nobori BES has comparable efficacy with other limus-eluting stents at 1-year follow-up. There is no difference in terms of safety profile between these stent platforms.
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. Electronic address: cassese@dhm.mhn.de.
authors.forename: Salvatore
authors.initials: S
authors.lastname: Cassese
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Fusaro
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Byrne
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Tada
authors.affiliation: DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
authors.forename: Petra
authors.initials: P
authors.lastname: Hoppmann
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Joner
authors.affiliation: DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
authors.forename: Karl-Ludwig
authors.initials: KL
authors.lastname: Laugwitz
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
authors.forename: Heribert
authors.initials: H
authors.lastname: Schunkert
authors.affiliation: Deutsches Herzzentrum, Technische Universität München, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
mesh_terms: D003324:Coronary Artery Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000639:trends*; D005500:Follow-Up Studies; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation / Q000639:trends; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: C518022:umirolimus; D020123:Sirolimus
keywords: Biolimus-eluting stent; Drug-eluting stent; Meta-analysis; Percutaneous coronary intervention